Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€263.80

€263.80

-0.080%
-0.2
-0.080%
€291.23
 
28.03.24 / Tradegate WKN: 867900 / Symbol: AMGN / Name: Amgen / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Amgen Inc. Stock

With only a change of -€0.200 (-0.080%) the Amgen Inc. price is nearly unchanged from yesterday.
Amgen Inc. is currently one of the favorites of our community with 20 Buy predictions and no Sell predictions.
With a target price of 291 € there is a slightly positive potential of 10.31% for Amgen Inc. compared to the current price of 263.8 €.
So far the community has only identified positive things for Amgen Inc. stock. The most positive votes were given for criterium "Brand".

Pros and Cons of Amgen Inc. in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Cons
?
B****
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Amgen Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Amgen Inc. -0.080% 3.289% 3.047% 19.991% 1.228% 23.041% 58.002%
Incyte Corp. 0.080% -0.677% -4.624% -19.451% -6.944% -23.853% -30.781%
Exact Sciences 6.010% 11.689% 23.210% 4.779% -6.581% -40.168% -13.146%
Regeneron Pharmaceuticals Inc. 0.220% -0.280% -2.304% 16.787% 11.661% 120.312% 147.733%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-14

Die Geldeinnahmen von Amgen (US-Symbol AMGN) deuten auf eine starke Leistung hin, die sich in entscheidenden Finanzmetriken wie Umsatz, Betriebskapital und Rentabilität widerspiegelt. Die Bilanzen des Unternehmens über die Jahre zeigen eine beständige Vermögensbasis und anhaltende Rentabilität. Die Analyse der Cashflow-Berichte zeigt, dass das Unternehmen robuste Betriebscashflows generiert, was auf solide betriebliche Leistung und Liquiditätsmanagement hindeutet.

Gehen wir tiefer in die einzelnen Vorteile und Nachteile der Finanzen von Amgen ein.

Die umfangreichen Vermögenswerte von Amgen, wie in den Jahresbilanzen gezeigt, beinhalten sowohl kurzfristige Vermögenswerte, die eine starke Liquidität signalisieren, als auch längerfristige Vermögenswerte, die eine solide Investition in den Forschungs- und Entwicklungsbereich verdeutlichen.

Comments

Prediction Buy
Perf. (%) -5.38%
Target price 305.575
Change
Ends at 07.02.25

Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at Royal Bank of Canada from $303.00 to $329.00. They now have an "outperform" rating on the stock.
Ratings data for AMGN provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -8.19%
Target price 324.870
Change
Ends at 07.02.25

Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $313.00 to $350.00. They now have a "buy" rating on the stock.
Ratings data for AMGN provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -10.35%
Target price 322.000
Change
Ends at 01.02.25

Amgen Inc. (NASDAQ: AMGN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $350.00 price target on the stock.
Ratings data for AMGN provided by MarketBeat
Show more

News

7 Stocks That Will Drive the Weight Loss Drugs Market: https://www.marketbeat.com/logos/articles/med_20240327132929_7-stocks-that-will-drive-the-weight-loss-drugs-mar.jpg
7 Stocks That Will Drive the Weight Loss Drugs Market

The global obesity epidemic has reached unprecedented proportions, causing severe health consequences and placing an immense economic burden on healthcare systems.  Pharmaceutical companies are

Is Amgen Stock a Buy Now?: https://g.foolcdn.com/editorial/images/769464/physician-giving-medicine-to-elderly-patient.jpg
Is Amgen Stock a Buy Now?

Biotech giant Amgen (NASDAQ: AMGN) isn't starting the year on a strong note. The company's shares are down by 5% since Jan. 1. It has dealt with some issues lately, especially subpar financial

4 Oversold Large Cap Stocks Yielding High Dividends: https://www.marketbeat.com/logos/articles/med_20240313190843_4-oversold-large-cap-stocks-yielding-high-dividend.jpg
4 Oversold Large Cap Stocks Yielding High Dividends

As the market continues its relentless ascent to new heights, propelled by the surging tech sector and hype surrounding AI,  the murmurs of potential interest rate cuts by the Federal Reserve